Skip to Content

Insulet reports year-over-year growth

Insulet reports year-over-year growth

ACTON, Mass. - Insulet Corp. reported revenue of $738.2 million for 2019, a 31% increase compared to 2018.

The company reported full-year revenue of $673.5 million for the Omnipod, broken down by U.S. revenue of $420.2 million and international revenue of $253.1 million, a 30% and 47% increase, respectively.

Insulet reported revenue of $209.4 million for the fourth quarter of 2019, a 27% increase compared to the same period in 2018. Operating income was $18.2 million.

"2019 was a remarkable year for Insulet, marked by disciplined execution of our strategy that allowed us to deliver consistent financial outperformance and strong operational results," said Shacey Petrovic, president and CEO. "With a solid foundation, pipeline of innovative technologies and proven strategy firmly in place, we made progress investing across our global organization to drive sustainable, long-term growth.”

Earlier this month, Insulet and DexCom announced they have partnered to combine current and future Dexcom CGMs with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System.


To comment on this post, please log in to your account or set up an account now.